Literature DB >> 11425463

Viral vectors as potential HIV-1 vaccines.

M J Schnell1.   

Abstract

Vaccine vectors based on recombinant viruses have great promise to play an important role in the development of an effective HIV-1 vaccine. Within the last 10 years a wide range of viruses have been investigated for their ability to express protein(s) from foreign pathogens and to induce specific immunological responses against these antigen(s) in vivo. Each viral vector has its own unique biological characteristics and thus far none of them has proven to be an ideal candidate as a vaccine vehicle for HIV-1. This review focuses on both replication competent and non-replication competent viral vectors as a potential HIV-1 vaccine. Other approaches for the development of an HIV-1 vaccine are reviewed elsewhere and are beyond the scope of this review.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425463     DOI: 10.1111/j.1574-6968.2001.tb10703.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  13 in total

1.  Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.

Authors:  Edward Nwanegbo; Eftyhia Vardas; Wentao Gao; Hilton Whittle; Huijie Sun; David Rowe; Paul D Robbins; Andrea Gambotto
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

Review 2.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

3.  Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.

Authors:  Chad Cecil; Ande West; Martha Collier; Christy Jurgens; Victoria Madden; Alan Whitmore; Robert Johnston; Dominic T Moore; Ronald Swanstrom; Nancy L Davis
Journal:  Virology       Date:  2007-02-01       Impact factor: 3.616

4.  Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene.

Authors:  Jonathan Cenna; Gene S Tan; Amy B Papaneri; Bernhard Dietzschold; Matthias J Schnell; James P McGettigan
Journal:  Vaccine       Date:  2008-09-18       Impact factor: 3.641

5.  A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.

Authors:  Amber Dunkel; Shixue Shen; Celia C LaBranche; David Montefiori; James P McGettigan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-05       Impact factor: 2.205

6.  Genetically stable picornavirus expression vectors with recombinant internal ribosomal entry sites.

Authors:  Andrew T Dufresne; Elena Y Dobrikova; Stacie Schmidt; Matthias Gromeier
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Authors:  Amando Zuniga; Mathias Liniger; Teldja Neige Azzouz Morin; René R Marty; Marian Wiegand; Orhan Ilter; Sara Weibel; Martin A Billeter; Marlyse C Knuchel; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

8.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  Applications and challenges of multivalent recombinant vaccines.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

10.  Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii.

Authors:  Gloria González-Aseguinolaza; Yurie Nakaya; Alberto Molano; Edward Dy; Mariano Esteban; Dolores Rodríguez; Juan Ramón Rodríguez; Peter Palese; Adolfo García-Sastre; Ruth S Nussenzweig
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.